SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
VVUS Analysis & Videos »
VVUS: Bull or Bear?
BioMed News Bytes: Arena (NASDAQ: ARNA), Momenta (NASDAQ:MNTA), Vivus (NASDAQ: VVUS)
VVUS
|
|
|
-32.67%
in
55 days
<> On 9/18/09, Arena Pharma (NASDAQ: ARNA) ($5.32, +9%) (heavy, above-average volume) announced lorcaserin met all primary endpoints and FDA benchmark with 63% of patients who complied with the protocol losing at least 5% of their weight. ARNA plans to file a NDA with the FDA in December. However, patients who took lorcaserin 10 mg twice daily achieved an average weight loss of 5.9% of their body weight, compared to 2.8% for placebo, causing shares of ARNA to initially decline on the news (with a recent turnaround and uptick) based on concerns for the commercial prospects of lorcaserin compar...
|
FDA Calendar: Five Weight Loss Trades
VVUS
|
|
|
+72.81%
in
59 days
(closed on 09/18/09)
<> Below are five small/micro-cap companies from the <font> BioMedReports.com FDA Calendar </font> with late-stage drugs or medical devices in development for prescription weight loss. Nearly two-thirds or 65% of U.S. population is classified as obese or overweight with a three-fold increase in adolescent obesity rates over the past three decades. Obesity is the second leading cause of preventable deaths behind smoking and weight loss is proven to decrease mortality while also improving blood sugar control in diabetics. Over one-third (35%) of people in the U.S. have a lifetime of devel...
|
Extreme FDA Calendar Trades: 18 Stocks Under $5
VVUS
|
|
|
+14.07%
in
18 days
(closed on 07/21/09)
<> Below are extreme trades among companies with stock prices under $5 from the <font> BioMedReports.com FDA Calendar </font> , which includes 232 entries as of 7/3/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissio...
|
NeuroSearch Experimental Obesity Drug to Begin Phase 3 Trials
VVUS
|
|
|
+5.17%
in
24 days
(closed on 07/03/09)
<> As a trio of U.S. small-cap drug makers await crucial Phase 3 results later this year; NeuroSearch (CPH:NEUR) (PINK:NEUSF) is preparing to advance its own experimental weight loss drug to the final stage of clinical development following a successful End of Phase 2 meeting with the FDA which was announced earlier this week. Arena Pharma (NASDAQ:ARNA), Vivus (NASDAQ:VVUS), and Orexigen Therapeutics (NASDAQ:OREX) are all awaiting Phase 3 clinical trial data expected during 3Q09 for their experimental weight loss drugs to support NDA filings for FDA approval, which are summarize...
|
FDA, Clinical Trial Calendars: Nine Cash Plus Catalyst Trades
VVUS
|
|
|
+26.07%
in
31 days
(closed on 06/09/09)
Below are nine 'Cash Plus Catalyst' trades which include companies that are currently trading for around 2X net cash/equivalents or less (the ratio of market cap to cash/equivalents less debt) with pending FDA decisions, clinical trial results, or pending FDA submissions. <font> Click here for a link </font> to the BioMedReports FDA and Clinical Trial Calendars page. <> 1.) BioForm Medical (NASDAQ:BFRM) : Market Cap = $59.8M, Net Cash = $41.4M. In March 2009, BioForm Medical announced the results of a clinical trial evaluating the mixing of lidocaine with RADIESSE derma...
|
FDA, Clinical Trial Calendar Updates: Weight Loss, Diabetes, and More
VVUS
|
|
|
+8.54%
in
38 days
(closed on 05/09/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 110 entries through 4/1/09. The FDA Calendar includes the following information: company name, ticker, decision d...
|
Vivus: A Buy on Well-Funded, Late-Stage Pipeline
VVUS
|
|
|
+28.93%
in
29 days
(closed on 04/01/09)
Vivus Inc. (VVUS) is a small-cap specialty pharma stock included in the ETF Innovators Preventive Medicine Index which is one of a trio of companies developing late-stage prescription weight loss drugs. <> Orexigen Therapeutics (OREX) will report additional Phase 3 results for Contrave around mid-year and hopes to file a NDA by year-end. Arena Pharma (ARNA) is expected to report Phase 3 results for lorcaserin by the end of this month. Vivus expects to post Phase 3 results around mid-year for Qnexa with a NDA filing planned before year-end. <> Nearly two-thirds...
|
A Calendar of Expected Clinical Trial Results
VVUS
|
|
|
-39.31%
in
51 days
(closed on 03/03/09)
<> 
The accompanying table [click to enlarge] includes 58 entries of expected clinical trial results in addition to pending FDA applications for new product approvals + a list of companies which will be required to re-submit their applications due to complete response letters from the agency.
See my recent article on 20 emerging healthcare stocks to watch in 2009 for more details on some of the companies included in the accompanying calendar, in addition to the following companies with near-term catalysts in...
|
20 Emerging Healthcare Stocks to Watch in '09
VVUS
|
|
|
+0.00%
in
16 hours
(closed on 01/11/09)
<> As a follow-up to my most recent article on the buyout binge among bio-pharma and diagnostic companies, below is a basket of 20 stocks (listed randomly) to consider from the ETF Innovators Indexes of 250 companies which represent a mix of pending catalysts in the form of clinical trials or FDA decisions, innovative patent portfolios or drug discovery technology platforms, promising compounds in clinical development, and marketed therapeutic or diagnostic products. Click on any of the company names for links to all of my prev...
|
People Bullish on VVUS
People Bearish on VVUS
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on VVUS |
More Resources
|
About VIVUS Inc.
- Answers.com
